Wu Zhuang

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen et al. · The Lancet Oncology · 2020 · 568 citations

Esophageal Cancer, Gastrointestinal Oncology, Medicine +10

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Jie Wang, Shun Lü, Xinmin Yu et al. · JAMA Oncology · 2021 · 381 citations · Full text

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

Yan Song, Bo Zhang, Dao Xin et al. · Nature Medicine · 2023 · 149 citations · Full text

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Jinwan Wang, Yan Sun, Qitao Yu et al. · PubMed · 2005 · 147 citations

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Yunpeng Yang, Jianya Zhou, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2019 · 135 citations

Biomarker Analysis, Medicine, Pharmacology +8